Molecular Profiling to ID Targeted Therapies Prolongs Patient Survival


Genetic sequencing of tumors to identify targeted therapy options appears to delay tumor progression and prolong patient survival.

Genetic sequencing of tumors to identify targeted therapy options appears to delay tumor progression and prolong patient survival, according to a retrospective exploratory analysis (abstract LBA2553) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1–5 in Chicago.

“Our findings show that molecular testing of tumors using next-generation sequencing can be used to optimize therapy and should be taken into consideration when selecting therapy for patients with difficult-to-treat cancers,” said lead study author Apostolia Maria Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston.

“This is the first and largest study-with the longest follow-up-to assess the impact of precision medicine approaches on survival across multiple cancer types,” Tsimberidou noted.

Implementation of precision oncology requires a “complete understanding” of tumor biology, including gene pathways and immune system factors that drive tumorigenesis, Tsimberidou said.

The authors analyzed data from 3,743 patients referred to molecular testing services at Clinical Laboratory Improvement Amendments–certified laboratories as part of their participation in the IMPACT (Initiative for Molecular Profiling and Advanced Cancer Therapy) clinical trial from 2007 to 2013. The number of genes tested varied between 1 and 50 during the study period. Twenty-four percent of patients had gastrointestinal cancers, 19% had gynecologic malignancies, 13.5% had breast cancer, 11.9% had melanoma, and 8.7% had lung cancer.

A total of 1,307 patients had at least one genetic alteration, 711 (54%) of whom received a targeted therapy based on their test results, and 596 (45.6%) of whom received therapy not matched to their tumor genetics.

Patients who were matched to a targeted therapy had a 3-year overall survival (OS) rate of 15% compared with 7% among patients who did not receive molecular testing–based treatment. The 10-year OS rate was 6% and 1%, respectively (hazard ratio, 0.72; P < .001). In a multivariate analysis, not receiving tumor gene–matched therapy, liver metastases, elevated lactate dehydrogenase levels, low albumin levels, elevated platelets, poor functional status, and patient age over 60 years were each significantly associated with poorer OS.

“Matched therapy was an independent factor predicting longer survival in multivariate analysis,” Tsimberidou said. “PI3K/AKT/mTOR pathway abnormalities were associated with inferior outcomes compared to other alterations.” The research team has developed a prognostic score for OS using that insight. The follow-up randomized phase II IMPACT 2 trial is ongoing.

“It’s been 20 years since the first targeted therapy was introduced,” commented ASCO Expert Catherine Diefenbach, MD, of the NYU Langone Medical Center in New York. “These first ‘precision-medicine’ therapies revolutionized cancer care and helped many patients live longer. But we’ve just scratched the surface. Now with faster and more robust genetic tests, we can help even more patients by treating the cancer based on its genetic makeup rather than solely on its location in the body.”

Related Videos
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Related Content